Brainsway Ltd.
BrainsWay develops and provides Deep Transcranial Magnetic Stimulation (Deep TMS) systems for noninvasive treatment of mental health disorders. Its customers are principally doctors, hospitals and medical centers in psychiatry. The system uses proprietary H-Coil helmets to deliver magnetic pulses, and includes a stimulator, user interface, positioning devices and cooling system. Cleared indications include major depressive disorder, obsessive-compulsive disorder and smoking addiction. BrainsWay also has CE Mark for various psychiatric and neurological indications. BrainsWay makes money through sales and leases of its Deep TMS systems, as well as related and other services. It offers flexible pricing models and sells and leases systems to treatment providers. Its principal executive offices are in Jerusalem, Israel, and it also has U.S. offices in Boston.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BRSYF in the last 30 days.
See all $BRSYF insider activity →BrainsWay Ltd reported a 34% revenue increase in Q3 2026, with gross margins expanding to 78%. CEO Hadar Levy expects continued growth and margin expansion into 2027, driven by a recurring-revenue model and strong demand for OCD coils. The company also highlighted international expansion and potential Alzheimer's research. Q3 operating cash flow was $6.2M, up from $1.4M a year earlier.
BrainsWay reported Q3 2026 revenue growth of 34% YoY to $18.1M, with gross margin at 78%. RPO increased 31% to $85M. Clinical trials showed promise in reducing suicidal ideation and treating depression with Alzheimer's. SWIFT protocol gained reimbursement access for 70M lives. The company invested $3M in Radial Health and partnered with Inland Psychiatric Medical Group. Operating income rose 107% YoY to $2.6M, with net income up 42% to $2.2M.
Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights Revenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million Remaining performance
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning BRSYF (Brainsway Ltd.). Coverage has skewed bullish: 4 bullish, 2 neutral, and 1 bearish.
Recent BRSYF coverage spans financial news and earnings.
Positive earnings surprise and upgraded guidance suggest upside potential.
BrainsWay reported Q3 2026 revenue growth of 34% YoY to $18.1M, with gross margin at 78%. RPO increased 31% to $85M. Clinical trials showed promise in reducing suicidal ideation and treating depression with Alzheimer's. SWIFT protocol gained reimbursement access for 70M lives. The company invested $3M in Radial Health and partnered with Inland Psychiatric Medical Group. Operating income rose 107% YoY to $2.6M, with net income up 42% to $2.2M.
Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights Revenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million Remaining performance
H.C. Wainwright reiterated a Buy rating and $19.00 price target for Brainsway (BWAY), citing a 71% upside potential. The company announced a strategic collaboration with Mindful Health Solutions to expand access to mental health treatments. Brainsway reported Q2 2026 revenue of $17.1 million, exceeding estimates, and raised its full-year revenue outlook to $68-$70 million. The stock has shown 32% revenue growth and a 75% gross profit margin over the last year.
BrainsWay Ltd. (BWAY) partnered with Mindful Health Solutions, a behavioral health provider, to expand access to its Deep TMS and SWIFT treatments. The collaboration includes education initiatives and research. BrainsWay also invested $0.8M in Heading Health's management services organization. The company develops neuromodulation therapies for mental health disorders, with FDA clearance for three indications.
AlphAI scores every news story that mentions BRSYF with an AI model for sentiment and relevance, and aggregates insider trades from Brainsway Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BrainsWay Ltd reported a 34% revenue increase in Q3 2026, with gross margins expanding to 78%. CEO Hadar Levy expects continued growth and margin expansion into 2027, driven by a recurring-revenue model and strong demand for OCD coils. The company also highlighted international expansion and potential Alzheimer's research. Q3 operating cash flow was $6.2M, up from $1.4M a year earlier.
BrainsWay reported Q3 2026 revenue growth of 34% YoY to $18.1M, with gross margin at 78%. RPO increased 31% to $85M. Clinical trials showed promise in reducing suicidal ideation and treating depression with Alzheimer's. SWIFT protocol gained reimbursement access for 70M lives. The company invested $3M in Radial Health and partnered with Inland Psychiatric Medical Group. Operating income rose 107% YoY to $2.6M, with net income up 42% to $2.2M.
Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights Revenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million Remaining performance
H.C. Wainwright reiterated a Buy rating and $19.00 price target for Brainsway (BWAY), citing a 71% upside potential. The company announced a strategic collaboration with Mindful Health Solutions to expand access to mental health treatments. Brainsway reported Q2 2026 revenue of $17.1 million, exceeding estimates, and raised its full-year revenue outlook to $68-$70 million. The stock has shown 32% revenue growth and a 75% gross profit margin over the last year.
BrainsWay Ltd. (BWAY) partnered with Mindful Health Solutions, a behavioral health provider, to expand access to its Deep TMS and SWIFT treatments. The collaboration includes education initiatives and research. BrainsWay also invested $0.8M in Heading Health's management services organization. The company develops neuromodulation therapies for mental health disorders, with FDA clearance for three indications.
H.C. Wainwright maintained a Buy rating and $19 price target for Brainsway (BWAY), citing expanded insurance coverage for its Deep TMS treatment. The stock trades at $11.93, with a P/E of 52 and PEG of 0.44. Brainsway reported Q2 2026 revenue of $17.1M, exceeding estimates, and raised its full-year outlook. The company also partnered with Inland Psychiatric Medical Group.
BrainsWay Ltd. (BWAY) announced that U.S. insurance policies covering its Deep TMS for OCD now reach over 118 million lives, indicating broader access and ongoing reimbursement momentum.
H.C. Wainwright reiterated a Buy rating and $19.00 price target on Brainsway (BWAY) following its partnership with Inland Psychiatric Medical Group. The stock has a 68% upside potential from its current price of $11.99. Brainsway reported Q2 2026 revenue of $17.1M, beating estimates, and raised its full-year revenue guidance to $68M-$70M, citing strong demand for its Deep TMS systems.
BrainsWay Ltd. (NASDAQ: BWAY) announced a strategic collaboration with Inland Psychiatric Medical Group (IPMG) to install Deep TMS systems and explore clinical research projects. BrainsWay's Deep TMS is FDA-cleared for treating major depressive disorder, OCD, and smoking addiction. The partnership aims to advance interventional psychiatry and mental health care in Southern California.
Bumble (BMBL) surged 56.7% to $5.96 after agreeing to a $6.05/share private takeover by Ithaca Holdings. Other movers: Fermi (FRMI) +22.5%, Enerflex (EFXT) +13.6%, BigBear.ai (BBAI) +9.1%, MongoDB (MDB) +6.8%, Xtend AI (XTND) +6.6%.
